Toxicity in the era of immune checkpoint inhibitor therapy

Immune checkpoint inhibitors (ICIs) reinvigorate anti-tumor immune responses by disrupting co-inhibitory immune checkpoint molecules such as programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4). Although ICIs have had unprecedented success and have become the standard of care...

詳細記述

書誌詳細

出版年:	Frontiers in Immunology
主要な著者:	Synat Keam, Naimah Turner, Fernanda G. Kugeratski, Rene Rico, Jocelynn Colunga-Minutti, Rayansh Poojary, Sayan Alekseev, Anisha B. Patel, Yuanteng Jeff Li, Ajay Sheshadri, Monica E. Loghin, Karin Woodman, Ashley E. Aaroe, Sarah Hamidi, Priyanka Chandrasekhar Iyer, Nicolas L. Palaskas, Yinghong Wang, Roza Nurieva
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2024-08-01
主題:	immune related adverse events immune checkpoint preclinical model immunotherapy treatment
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1447021/full